IFNA1 and renal cell carcinoma: Because ET-1 and ETAR are overexpressed in RCC (Douglas et al, 2004; Pflug et al, 2007), suggesting pathological endothelin signalling, and because of complementary mechanisms of action exercised by atrasentan and IFN-α, we hypothesised that mRCC patients might benefit from combining these agents.